Drugs / autologous NK cells
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04558853 | Jan 2014 → Dec 2021 | plasma cell myeloma | Karolinska University Hospital | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07260058 | Dec 2025 → Jun 2027 expected | breast cancer, colorectal cancer, liver cancer, lung cancer | Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06948994 | May 2025 → Apr 2027 expected | neuroblastoma | Guangzhou Women and Children's Medical Center | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07552233 | Apr 2026 → Dec 2030 expected | glioblastoma, meningioma, metastatic malignant neoplasm in the brain | Peking University Third Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous NK cells | “2. Autologous NK Cells：Natural Killer (NK) cells are manufactured ex vivo from the participant's own peripheral blood mononuclear cells (PBMCs).” NCT07260058 ↗3“Combination of autologous NK cells and GD2 monoclonal antibody” NCT06948994 ↗ |
| Known as | natural killer (NK) cells | “This is a multi-center, open-label investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, and feasibility of combined intracranial and intravenous...” NCT07552233 ↗ |
| Modality | Cell therapy | “cell suspension based on ex vivo expanded NK cells” NCT04558853 ↗ |
| Route | Intravenous | “Mode of administration Intravenous infusions” NCT04558853 ↗ |